Pharma

Pharma

New approvals set to revolutionize myelofibrosis treatment landscape across 8MM, says GlobalData

The treatment paradigm for myelofibrosis (MF) – a rare type of blood cancer – is expected to experience marked transformation over the next decade in the world’s eight major markets (8MM*) due to numerous late-stage pipeline therapies potentially becoming the new standards of care, according to GlobalData, a leading data and analytics company. GlobalData’s latest […]

Pharma

Strong safety data to support etrasimod entry to ulcerative colitis market, says GlobalData

The market for ulcerative colitis (UC) is filled with a number of different treatment options, and the pipeline is relatively strong. Pfizer’s etrasimod is a notable agent in the late-stage UC pipeline which is a once-daily oral sphingosine-1-phosphate (S1P) modulator. The company recently presented long-term safety data spanning 2.5 years at the Digestive Disease Week […]

Pharma

AbbVie’s Rinvoq for Crohn’s Disease to see rapid uptake by healthcare providers, says GlobalData

The FDA recently announced the approval of Rinvoq (upadacitinib), AbbVie’s Janus kinase inhibitor (JAKi), to treat adults with moderately to severely active Crohn’s Disease (CD) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. The decision was based on data from two randomized induction trials, U-EXCEED (NCT03345836) […]

Pharma

Alnylam patent lawsuit against Pfizer, Moderna highlights escalating legal pressure on big pharma companies, says GlobalData

Biotech company Alnylam Pharmaceuticals has filed a third patent lawsuit against Pfizer and Moderna, alleging unauthorized use of its proprietary lipid nanoparticle (LNP) vaccine delivery technology in their COVID-19 vaccines. This move highlights the escalating legal pressure on big pharma companies as they face multiple claims related to LNP technology, with Alnylam seeking substantial royalty […]

Pharma

Janssen Tremfya excels as psoriasis treatment, outshining IL-17s, says GlobalData

Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson (J&J), has recently released new data on Tremfya (guselkumab), a monoclonal antibody that targets IL-23 in adults with moderate-to-severe plaque psoriasis (PsO). Tremfya, the first approved IL-23 inhibitor in the US, has potential for various indications and is forecasted to generate $8.6 billion in global sales by […]

Pharma

Novo Nordisk’s limit on Wegovy supply vital to retain its competitive advantage, says GlobalData

Novo Nordisk recently announced that the starter doses of Wegovy (semaglutide) would be limited in the US until September, in an effort to avoid supply shortages. The move comes after the company faced a supply shortage issue in March 2022, which resulted in halted sales of Wegovy and a delay in launching in the EU. […]

Pharma

China poised to lead the way with world’s first oral insulin for type 2 diabetes, says GlobalData

Hefei Tianhui Biotechnology Co. Ltd. (HTIT) has recently submitted a marketing authorization application (MAA) in China for the world’s first oral insulin for type 2 diabetes (T2D). If approved, China will become the world’s first country with oral insulin availability, says GlobalData, a leading data and analytics company. According to GlobalData’s Pharma Intelligence Center, there are […]

Pharma

Parkinson’s unmet needs present significant opportunity for new entrants, says GlobalData

Parkinson’s Disease (PD) is a complex, multi-system neurodegenerative disorder that affects movement control. Current treatments focus on the management of dopamine levels in the brain, with levodopa-based therapies remaining the standard of care in the PD market for the past half century. However, the effectiveness of levodopa declines with time, and both motor and non-motor […]

Pharma

New study findings hold potential for new treatment option to prevent stroke in AF patients, says GlobalData

At the 2023 annual congress of the European Heart Rhythm Association (EHRA 2023), new real-world data was presented by researchers from Hong Kong, demonstrating that the risk of strokes was lower in atrial fibrillation (AF) patients who had been using statins within a year of their diagnosis. While the benefit of statins in AF patients […]

Pharma

Tibsovo’s EU approval game changer for patients with acute myeloid leukemia and bile duct cancer in Europe, says Globaldata

Servier Pharmaceuticals recently announced the European Commission (EC) approval of Tibsovo (ivosidenib), as a targeted therapy in two difficult-to-treat oncology indications, acute myeloid leukemia (AML) and advanced cholangiocarcinoma. This marks the first IDH1 inhibitor approved in Europe and will be a game changer for patients with AML and cholangiocarcinoma in Europe, as Tibsovo addresses the […]

Pharma

Immatics’ IMA203 clinical data to boost TCR-T therapy development in solid tumour, says GlobalData

Immunotherapy-focused biotech Immatics recently announced encouraging interim clinical data from one of the three cohorts of its Phase Ib trial evaluating its leading T-cell receptor-based T-cell (TCR-T) therapy candidate, IMA203. The positive data represents considerable progress in the development of adoptive cell therapies (ACTs) for the treatment of solid cancers, says GlobalData, a leading data […]

Pharma

Ultomiris, Hemlibra, Vafseo instrumental in driving hematological disorders market, reveals GlobalData

The hematological disorders market is undergoing an impressive surge in sales, cementing its position as the fastest-growing therapy area for the second consecutive year. Notably, this growth is not evenly distributed, with 45% of the sales growth being driven by just three drugs: Alexion Pharmaceuticals’s Ultomiris (ravulizumab-cwvz), Genentech’s Hemlibra (emicizumab-kxwh), and Akebia Therapeutics’s Vafseo (vadadustat), […]

Pharma

Phase I completion of Sanofi vWD therapy demonstrates significant potential of pipeline, says GlobalData

Sanofi has successfully completed the Phase I trial for its von Willebrand disease (vWD) therapy, efanesoctocog alfa (BIV001), a novel antihemophilic factor recombinant fusion protein that acts as a coagulation factor VIII therapy. This is a significant potential addition to the future of the late stage vWD pipeline, which currently lacks novel molecules and therapies […]

Pharma

Competition for therapies targeting folate receptor alpha expected to intensify, says GlobalData

Global market for FRα-targeted therapy in cancer is expected to increase from $3 million in 2022 to $921 million in 2029, with a CAGR of 126.7% ImmunoGen’s Elahere is at the forefront of the race in terms of development and is the only FRα therapy approved in the oncology field The increasing competition in this […]

Pharma

Cost of disease-modifying therapies for multiple sclerosis continues to rise in US, finds GlobalData

The cost of disease-modifying therapies (DMTs) for multiple sclerosis (MS) patients in the US has increased since 2020, placing an increasing financial strain on patients, their families, and the healthcare system, says GlobalData, a leading data and analytics company. According to GlobalData’s recent ‘Multiple Sclerosis: Seven-Market Drug Forecast and Market Analysis to 2030 – Update’ […]

Pharma

Immuno-oncology agents to continue transforming cancer treatment landscape, says GlobalData

Immuno-oncology (IO) agents have transformed the oncology landscape in the last decade, particularly immune checkpoint inhibitors (ICIs) in solid tumor settings and chimeric antigen receptor (CAR) T-cells in hematological malignancies, with patients who previously had very limited therapeutic options achieving long term remissions and even cure. Continued investment into IO R&D in both academia and […]

Pharma

Farxiga’s expanded approval highlights potential to differentiate in HF space, says GlobalData

Farxiga’s (dapagliflozin) recent approvals will help a broader range of patients with heart failure (HF) in the US. Resultantly, AstraZeneca is expected to see a significant boost in its revenues. Farxiga is expected to have such a strong influence on the market due to the impressive results and valuable evidence seen in recent trials. The […]

Pharma

Novavax AI approach to COVID-influenza vaccine design pays off in Phase II trial, says GlobalData

Artificial intelligence (AI) has been fundamental to the development of Novavax’s COVID-Influenza Combination (CIC) vaccine reflecting a wider industry trend for increased usage of AI in clinical trial design, says GlobalData, a leading data and analytics company. Novavax has recently announced topline results from a Phase II trial for its CIC vaccine. The data indicates […]

Pharma

Novo Nordisk’s blockbuster Ozempic sales to surge by 23% in 2023, forecasts GlobalData

Novo Nordisk’s leading drug Ozempic (semaglutide) is forecast to demonstrate a growth of 23% in its sales to $12.5 billion in 2023, consolidating its position as the dominant market leader, as projected sales will be 54% greater than closest competitor Trulicity (dulaglutide) by Eli Lilly, which anticipates sales of $8 billion, says GlobalData, a leading […]

Pharma

Ultragenyx’s UX053 Phase I/II study termination a minor setback for mRNA therapeutics, says GlobalData

Ultragenyx has terminated its Phase I/II trial for pipeline candidate UX053, a non-vaccine mRNA therapeutic for glycogen storage disease type III, also known as Cori’s disease. The study was terminated due to reasons unrelated to safety concerns, although the specific rationale has not been disclosed by the biopharmaceutical company. mRNA therapeutics hold a lot of […]

Prev 1 … 35 36 37 38 39 … 110 Next

New approvals set to revolutionize myelofibrosis treatment landscape across 8MM, says GlobalData

Strong safety data to support etrasimod entry to ulcerative colitis market, says GlobalData

AbbVie’s Rinvoq for Crohn’s Disease to see rapid uptake by healthcare providers, says GlobalData

Alnylam patent lawsuit against Pfizer, Moderna highlights escalating legal pressure on big pharma companies, says GlobalData

Janssen Tremfya excels as psoriasis treatment, outshining IL-17s, says GlobalData

Novo Nordisk’s limit on Wegovy supply vital to retain its competitive advantage, says GlobalData

China poised to lead the way with world’s first oral insulin for type 2 diabetes, says GlobalData

Parkinson’s unmet needs present significant opportunity for new entrants, says GlobalData

New study findings hold potential for new treatment option to prevent stroke in AF patients, says GlobalData

Tibsovo’s EU approval game changer for patients with acute myeloid leukemia and bile duct cancer in Europe, says Globaldata

Immatics’ IMA203 clinical data to boost TCR-T therapy development in solid tumour, says GlobalData

Ultomiris, Hemlibra, Vafseo instrumental in driving hematological disorders market, reveals GlobalData

Phase I completion of Sanofi vWD therapy demonstrates significant potential of pipeline, says GlobalData

Competition for therapies targeting folate receptor alpha expected to intensify, says GlobalData

Cost of disease-modifying therapies for multiple sclerosis continues to rise in US, finds GlobalData

Immuno-oncology agents to continue transforming cancer treatment landscape, says GlobalData

Farxiga’s expanded approval highlights potential to differentiate in HF space, says GlobalData

Novavax AI approach to COVID-influenza vaccine design pays off in Phase II trial, says GlobalData

Novo Nordisk’s blockbuster Ozempic sales to surge by 23% in 2023, forecasts GlobalData

Ultragenyx’s UX053 Phase I/II study termination a minor setback for mRNA therapeutics, says GlobalData

Browse

Company information